Oncolytic Adenovirus with SPAG9 shRNA Driven by DD3 Promoter Improved the Efficacy of Docetaxil for Prostate Cancer

Meng Lu; Fu-Kun Wei; Chuang Wu; Zi-Yang Xu; Li-Jun Mao; Dong-Rong Yang

doi:10.1155/2022/7918067

Oncolytic Adenovirus with SPAG9 shRNA Driven by DD3 Promoter Improved the Efficacy of Docetaxil for Prostate Cancer

J Oncol. 2022 Apr 30:2022:7918067. doi: 10.1155/2022/7918067. eCollection 2022.

Authors

Meng Lu^{1

2}, Fu-Kun Wei², Chuang Wu², Zi-Yang Xu², Li-Jun Mao², Dong-Rong Yang¹

Affiliations

¹ Department of Urology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, Jiangsu Province, China.
² Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China.

Abstract

Prostate cancer (PCa) is a common malignant tumor of the male urinary system and ranks the second in the causes of tumor-related deaths. Differential display code 3 (DD3) is a noncoding gene that is specifically expressed in PCa. High expression of sperm-associated antigen 9 (SPAG9) is closely related to tumorigenesis of PCa, and SPAG9 is a therapeutic target for PCa. In this study, a new oncolytic adenovirus DD3-ZD55-SPAG9 was constructed by using DD3 promoter to enhance the efficacy and safety of adenovirus. The combined use of DD3-ZD55-SPAG9 and docetaxel showed that DD3-ZD55-SPAG9 significantly improved the anti-tumor efficacy of docetaxel in PCa both in vitro and in vivo. The mechanism was related to the induction of tumor cell apoptosis and the inhibition of tumor cell invasion. In conclusion, DD3-ZD55-SPAG9 combined with docetaxel is an effective strategy for PCa therapy.